1,768 reports of this reaction
2.7% of all IPILIMUMAB reports
#7 most reported adverse reaction
RASH is the #7 most commonly reported adverse reaction for IPILIMUMAB, manufactured by E.R. Squibb & Sons, L.L.C.. There are 1,768 FDA adverse event reports linking IPILIMUMAB to RASH. This represents approximately 2.7% of all 65,125 adverse event reports for this drug.
Patients taking IPILIMUMAB who experience rash should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RASH is a less commonly reported adverse event for IPILIMUMAB, but still significant enough to appear in the safety profile.
In addition to rash, the following adverse reactions have been reported for IPILIMUMAB:
The following drugs have also been linked to rash in FDA adverse event reports:
RASH has been reported as an adverse event in 1,768 FDA reports for IPILIMUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
RASH accounts for approximately 2.7% of all adverse event reports for IPILIMUMAB, making it a notable side effect.
If you experience rash while taking IPILIMUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.